Key facts
- It has raised $7.0M; the latest was Seed Round ($5.5M) in Nov 2025.
- Notable investors include U.S. Department of Energy, BioAdvance Capital (Conshohocken), Medical Excellence Capital, Bowman's Tower Venture Partners, Hatch Biofund Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Ladder Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ladder Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ladder Bio
Developer of a synthetic technology and computational chemistry platform designed for spiroligomers and other unnatural molecules. The company's platform helps to develop novel diagnostics and drug-like chemical entities that combine the pharmaceutical properties of small molecules with the selectivity of peptides and proteins for diagnostics and medicine applications, enabling medical professionals to advance alchemical calculations for molecular packages.
- Sector
- Healthcare
- HQ
- Blue Bell, PA, United States
- Founded
- 2018
- Website
- ladderbio.com/
- Ownership
- Privately Held (backing)
Ladder Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ladder Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ladder Bio in its N-PORT filings yet. We sweep new filings monthly.